Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Magenta Therapeutics stock

Own Magenta Therapeutics stock in just a few minutes.

Posted

Fact checked

Magenta Therapeutics, Inc is a biotechnology business based in the US. Magenta Therapeutics shares (MGTA) are listed on the NASDAQ and all prices are listed in US Dollars. Magenta Therapeutics employs 70 staff and has a market cap (total outstanding shares value) of USD$314.5 million.

How to buy shares in Magenta Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Magenta Therapeutics. Find the stock by name or ticker symbol: MGTA. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Magenta Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Magenta Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Magenta Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Magenta Therapeutics share price

Use our graph to track the performance of MGTA stocks over time.

Magenta Therapeutics shares at a glance

Information last updated 2020-11-24.
52-week range USD$5.76 - USD$16.19
50-day moving average USD$6.8739
200-day moving average USD$7.7775
Wall St. target price USD$16.67
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-1.908

Buy Magenta Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Magenta Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Magenta Therapeutics financials

Gross profit TTM USD$0
Return on assets TTM -29.94%
Return on equity TTM -49.99%
Profit margin 0%
Book value $3.298
Market capitalisation USD$314.5 million

TTM: trailing 12 months

Shorting Magenta Therapeutics shares

There are currently 1.9 million Magenta Therapeutics shares held short by investors – that's known as Magenta Therapeutics's "short interest". This figure is 16.1% up from 1.6 million last month.

There are a few different ways that this level of interest in shorting Magenta Therapeutics shares can be evaluated.

Magenta Therapeutics's "short interest ratio" (SIR)

Magenta Therapeutics's "short interest ratio" (SIR) is the quantity of Magenta Therapeutics shares currently shorted divided by the average quantity of Magenta Therapeutics shares traded daily (recently around 184070.41420118). Magenta Therapeutics's SIR currently stands at 10.14. In other words for every 100,000 Magenta Therapeutics shares traded daily on the market, roughly 10140 shares are currently held short.

However Magenta Therapeutics's short interest can also be evaluated against the total number of Magenta Therapeutics shares, or, against the total number of tradable Magenta Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Magenta Therapeutics's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Magenta Therapeutics shares in existence, roughly 40 shares are currently held short) or 0.0629% of the tradable shares (for every 100,000 tradable Magenta Therapeutics shares, roughly 63 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Magenta Therapeutics.

Find out more about how you can short Magenta Therapeutics stock.

Magenta Therapeutics share dividends

We're not expecting Magenta Therapeutics to pay a dividend over the next 12 months.

Magenta Therapeutics share price volatility

Over the last 12 months, Magenta Therapeutics's shares have ranged in value from as little as $5.76 up to $16.19. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Magenta Therapeutics's is 2.5611. This would suggest that Magenta Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Magenta Therapeutics overview

Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops novel medicines to extend the curative power of stem cell transplant, gene therapy, genome editing, and cell therapy to patients. Thecompany is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a novel stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an antibody-drug conjugate program to prevent acute graft and host diseases. It has a has a research and clinical collaboration agreement with AVROBIO, Inc.to evaluate targeted antibody-drug conjugate as a conditioning regimen for lentiviral gene therapies. The company was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. Magenta Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site